Our data suggest that selective inhibition of COX-2 by NSAIDs or cannabidiolic acid which is the acidic precursor of cannabidiol, a non-psychoactive component of cannabis (Takeda et al., 2008), may be useful for treating not only cognitive impairments (Chen et al., 2013), but also the aversive effects and possibly some other side effects of medical or recreational administrations of marijuana. This evidence concerns the gene PTGS2 and Cognitive impairment.